Getein Biotech, Inc. Class A

Getein Biotech, Inc. Class A

SSSE:603387
8.26
CNY
+0.06
(+0.73%)
0.58EPS
17.33P/E
5.08BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Getein Biotech, Inc. Class A carries a market capitalization of 5.08B, placing it among publicly traded companies globally. Its enterprise value stands at 3.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.08B
Enterprise Value3.79B

Share Statistics

As of September 30, 2026, Getein Biotech, Inc. Class A has 507.15M shares outstanding.

Shares Outstanding507.15M

Valuation Ratios

As of September 30, 2026, Getein Biotech, Inc. Class A trades at a trailing price-to-earnings ratio of 17.33. The price-to-sales ratio is 4.55, and the price-to-book ratio stands at 1.75.

PE Ratio17.33
PS Ratio4.55
PB Ratio1.75
P/TBV Ratio1.88

Enterprise Valuation

As of September 30, 2026, Getein Biotech, Inc. Class A trades at an EV/EBITDA multiple of 11.71 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.71 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.79B versus a market cap of 5.08B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.41
EV / EBITDA11.71
EV / EBIT11.71

Financial Position

As of September 30, 2026, Getein Biotech, Inc. Class A maintains a current ratio of 3.84, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.21, indicating elevated leverage, while an interest coverage ratio of 37.26 demonstrates strong ability to service its debt obligations.

Current Ratio3.84
Quick Ratio2.59
Debt / Equity9.21
Debt / EBITDA0.86
Interest Coverage37.26

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Getein Biotech, Inc. Class A posted a return on equity (ROE) of 10.47, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.64 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.69, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.87, useful for judging operating efficiency across full business cycles. The company generates approximately 642,921.46 in revenue per employee across its workforce of 1,733.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.81 indicates how many times Getein Biotech, Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)10.47
Return on Assets (ROA)7.69
Return on Invested Capital (ROIC)8.64
Return on Capital Employed (ROCE)8.87
Revenue Per Employee642,921.46
Employee Count1,733.00
Inventory Turnover1.81

Taxes

CNY

Over the twelve months ended September 30, 2026, Getein Biotech, Inc. Class A recorded 29.36M in income tax expense. That works out to an effective tax rate of 9.12, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 321.88M, leaving 292.52M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax29.36M
Effective Tax Rate9.12

Stock Price Statistics

CNY

As of the close on November 17, 2026, Getein Biotech, Inc. Class A's stock has declined approximately 4.40% over the past 52 weeks. The 50-day moving average sits at 9.15, while the 200-day moving average is 9.01.

52-Week Price Change-4.40%
50-Day Moving Average9.15
200-Day Moving Average9.01

Income Statement

CNY

Over the twelve months ended September 30, 2026, Getein Biotech, Inc. Class A generated 1.11B in revenue and converted that into 292.52M in net income, yielding earnings per share of 0.58. EBITDA reached 324.00M, while operating income came in at 307.62M.

Revenue1.11B
Gross Profit778.87M
Operating Income307.62M
Pretax Income321.88M
Net Income292.52M
EBITDA324.00M
EBIT324.00M
Earnings Per Share (EPS)0.58

Balance Sheet

CNY

As of September 30, 2026, Getein Biotech, Inc. Class A holds 1.66B in cash and equivalents against 277.28M in total debt, resulting in a net debt position of -75.51M. Total book value stands at 2.91B, with working capital of 1.82B providing operational flexibility.

Cash & Cash Equivalents1.66B
Total Debt277.28M
Net Debt-75.51M
Equity (Book Value)2.91B
Book Value Per Share5.73
Working Capital1.82B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-120.87M

Margins

Over the twelve months ended September 30, 2026, Getein Biotech, Inc. Class A posted a gross margin of 69.91, reflecting its pricing power and cost economics. The operating margin of 27.61 and net profit margin of 26.25 provide insight into operational efficiency.

Gross Margin69.91
Operating Margin27.61
Pretax Margin28.89
Profit Margin26.25
EBITDA Margin29.08

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Getein Biotech, Inc. Class A paid dividends of 0.33 per share. The dividend payout ratio of 56.73 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 10.41, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Getein Biotech, Inc. Class A shareholders.

Dividend Per Share0.33
Payout Ratio56.73
Shareholder Yield10.41

Stock Splits

Getein Biotech, Inc. Class A's most recent stock split took place on June 8, 2022 with a 5:7 split ratio.

Last Split Date6/8/2022
Split Ratio5:7

Scores

As of September 30, 2026, Getein Biotech, Inc. Class A has an Altman Z-Score of 6.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.40